Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

Friday, 1 Sep 2017 

Sept 1 (Reuters) - Sosei Group Corp <4565.T>:Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study .Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016. 

Company Quote

12 Jul 2019